Global Noninvasive Prenatal Testing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Noninvasive Prenatal Testing Market is presumed to reach the market size of nearly USD 4.96 Billion by 2032 from USD 4.71 Billion in 2023 with a CAGR of 0.58% under the study period 2024-2032.

Noninvasive prenatal testing (NIPT) is a screening method used to identify genetic anomalies in a developing fetus without resorting to invasive procedures like amniocentesis or chorionic villus sampling. NIPT analyzes cell-free fetal DNA circulating in the mother's bloodstream to assess the risk of chromosomal disorders, including Edwards syndrome (trisomy 18), Down syndrome (trisomy 21), and Patau syndrome (trisomy 13), as well as specific sex chromosome abnormalities. NIPT offers a safer and more accurate option compared to traditional prenatal testing methods, with results typically available early in pregnancy.

MARKET DYNAMICS

The factors driving the noninvasive prenatal testing market include the spurring demand for early & accurate detection of fetal abnormalities, the growing adoption of noninvasive prenatal screening tests, and advancements in genetic testing technologies. With the rising maternal age and the increasing awareness of prenatal screening options, there is a growing demand for noninvasive prenatal testing. Additionally, technological advancements in sequencing technologies, bioinformatics, and genetic analysis methods drive innovation in NIPT, offering improved accuracy, sensitivity, and specificity in detecting fetal genetic abnormalities. Moreover, the expanding range of genetic conditions screened by NIPT, including microdeletions and sex chromosome aneuploidies, further stimulates market growth by addressing unmet clinical needs and improving patient care. Furthermore, the endorsement of NIPT by professional medical societies and regulatory agencies and reimbursement coverage by healthcare payers enhances accessibility and adoption of NIPT among pregnant women. However, regulatory hurdles and reimbursement challenges may hinder the growth of the noninvasive prenatal testing market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Noninvasive Prenatal Testing. The growth and trends of Noninvasive Prenatal Testing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Noninvasive Prenatal Testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Gestation Period

0-12 Weeks
13-24 Weeks
25-36 Weeks

By Pregnancy Risk

High & Average Risk
Low Risk

By Method

Ultrasound Detection
Biochemical Screening Tests
Cell-free DNA in Maternal Plasma Tests

By Technology

NGS
Array Technology
PCR
Others

By Product

Consumables & Reagents
Instruments

By Application

Trisomy
Microdeletion Syndrome
Other Applications

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Noninvasive Prenatal Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Noninvasive Prenatal Testing market include Genesis Genetics (CooperSurgical Inc.), Natera Inc., Centogene N.V., Illumina Inc. (Verinata Health Inc.), Eurofins LifeCodexx GmbH, MedGenome Labs Ltd., F. Hoffmann-La Roche Ltd., (Ariosa Diagnostics), Myriad Women'S Health Inc. (Counsyl Inc.), QIAGEN, Laboratory Corp. Of America Holdings, Progenity Inc., Quest Diagnostics Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11214554

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. NONINVASIVE PRENATAL TESTING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Gestation Period
- 3.7.2 Market Attractiveness Analysis By Pregnancy Risk
- 3.7.3 Market Attractiveness Analysis By Method
- 3.7.4 Market Attractiveness Analysis By Technology
- 3.7.5 Market Attractiveness Analysis By Product
- 3.7.6 Market Attractiveness Analysis By Application
- 3.7.7 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GESTATION PERIOD

5.1. Overview By Gestation Period
5.2. Historical and Forecast Data
5.3. Analysis By Gestation Period
5.4. 0-12 Weeks Historic and Forecast Sales By Regions
5.5. 13-24 Weeks Historic and Forecast Sales By Regions
5.6. 25-36 Weeks Historic and Forecast Sales By Regions

6. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY PREGNANCY RISK

6.1. Overview By Pregnancy Risk
6.2. Historical and Forecast Data
6.3. Analysis By Pregnancy Risk
6.4. High & Average Risk Historic and Forecast Sales By Regions
6.5. Low Risk Historic and Forecast Sales By Regions

7. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY METHOD

7.1. Overview By Method
7.2. Historical and Forecast Data
7.3. Analysis By Method
7.4. Ultrasound Detection Historic and Forecast Sales By Regions
7.5. Biochemical Screening Tests Historic and Forecast Sales By Regions
7.6. Cell-free DNA in Maternal Plasma Tests Historic and Forecast Sales By Regions

8. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY TECHNOLOGY

8.1. Overview By Technology
8.2. Historical and Forecast Data
8.3. Analysis By Technology
8.4. NGS Historic and Forecast Sales By Regions
8.5. Array Technology Historic and Forecast Sales By Regions
8.6. PCR Historic and Forecast Sales By Regions
8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY PRODUCT

9.1. Overview By Product
9.2. Historical and Forecast Data
9.3. Analysis By Product
9.4. Consumables & Reagents Historic and Forecast Sales By Regions
9.5. Instruments Historic and Forecast Sales By Regions

10. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY APPLICATION

10.1. Overview By Application
10.2. Historical and Forecast Data
10.3. Analysis By Application
10.4. Trisomy Historic and Forecast Sales By Regions
10.5. Microdeletion Syndrome Historic and Forecast Sales By Regions
10.6. Other Applications Historic and Forecast Sales By Regions

11. GLOBAL NONINVASIVE PRENATAL TESTING MARKET ANALYSIS BY GEOGRAPHY

11.1. Regional Outlook
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1 Overview, Historic and Forecast Data Sales Analysis
- 11.3.2 North America By Segment Sales Analysis
- 11.3.3 North America By Country Sales Analysis
- 11.3.4 United States Sales Analysis
- 11.3.5 Canada Sales Analysis
- 11.3.6 Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1 Overview, Historic and Forecast Data Sales Analysis
- 11.4.2 Europe By Segment Sales Analysis
- 11.4.3 Europe By Country Sales Analysis
- 11.4.4 United Kingdom Sales Analysis
- 11.4.5 France Sales Analysis
- 11.4.6 Germany Sales Analysis
- 11.4.7 Italy Sales Analysis
- 11.4.8 Russia Sales Analysis
- 11.4.9 Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1 Overview, Historic and Forecast Data Sales Analysis
- 11.5.2 Asia Pacific By Segment Sales Analysis
- 11.5.3 Asia Pacific By Country Sales Analysis
- 11.5.4 China Sales Analysis
- 11.5.5 India Sales Analysis
- 11.5.6 Japan Sales Analysis
- 11.5.7 South Korea Sales Analysis
- 11.5.8 Australia Sales Analysis
- 11.5.9 South East Asia Sales Analysis
- 11.5.10 Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1 Overview, Historic and Forecast Data Sales Analysis
- 11.6.2 Latin America By Segment Sales Analysis
- 11.6.3 Latin America By Country Sales Analysis
- 11.6.4 Brazil Sales Analysis
- 11.6.5 Argentina Sales Analysis
- 11.6.6 Peru Sales Analysis
- 11.6.7 Chile Sales Analysis
- 11.6.8 Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1 Overview, Historic and Forecast Data Sales Analysis
- 11.7.2 Middle East & Africa By Segment Sales Analysis
- 11.7.3 Middle East & Africa By Country Sales Analysis
- 11.7.4 Saudi Arabia Sales Analysis
- 11.7.5 UAE Sales Analysis
- 11.7.6 Israel Sales Analysis
- 11.7.7 South Africa Sales Analysis
- 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE NONINVASIVE PRENATAL TESTING COMPANIES

12.1. Noninvasive Prenatal Testing Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13. COMPANY PROFILES OF NONINVASIVE PRENATAL TESTING INDUSTRY

13.1. Top Companies Market Share Analysis
13.2. Market Concentration Rate
13.3. Genesis Genetics (CooperSurgical Inc.)
- 13.3.1 Company Overview
- 13.3.2 Company Revenue
- 13.3.3 Products
- 13.3.4 Recent Developments
13.4. Natera Inc.
- 13.4.1 Company Overview
- 13.4.2 Company Revenue
- 13.4.3 Products
- 13.4.4 Recent Developments
13.5. Centogene N.V.
- 13.5.1 Company Overview
- 13.5.2 Company Revenue
- 13.5.3 Products
- 13.5.4 Recent Developments
13.6. Illumina Inc. (Verinata Health Inc.)
- 13.6.1 Company Overview
- 13.6.2 Company Revenue
- 13.6.3 Products
- 13.6.4 Recent Developments
13.7. Eurofins LifeCodexx GmbH
- 13.7.1 Company Overview
- 13.7.2 Company Revenue
- 13.7.3 Products
- 13.7.4 Recent Developments
13.8. MedGenome Labs Ltd.
- 13.8.1 Company Overview
- 13.8.2 Company Revenue
- 13.8.3 Products
- 13.8.4 Recent Developments
13.9. F. Hoffmann-La Roche Ltd.
- 13.9.1 Company Overview
- 13.9.2 Company Revenue
- 13.9.3 Products
- 13.9.4 Recent Developments
13.10. (Ariosa Diagnostics)
- 13.10.1 Company Overview
- 13.10.2 Company Revenue
- 13.10.3 Products
- 13.10.4 Recent Developments
13.11. Myriad Women'S Health Inc. (Counsyl Inc.)
- 13.11.1 Company Overview
- 13.11.2 Company Revenue
- 13.11.3 Products
- 13.11.4 Recent Developments
13.12. QIAGEN
- 13.12.1 Company Overview
- 13.12.2 Company Revenue
- 13.12.3 Products
- 13.12.4 Recent Developments
13.13. Laboratory Corp. Of America Holdings
- 13.13.1 Company Overview
- 13.13.2 Company Revenue
- 13.13.3 Products
- 13.13.4 Recent Developments
13.14. Progenity Inc.
- 13.14.1 Company Overview
- 13.14.2 Company Revenue
- 13.14.3 Products
- 13.14.4 Recent Developments
13.15. Quest Diagnostics Inc
- 13.15.1 Company Overview
- 13.15.2 Company Revenue
- 13.15.3 Products
- 13.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies